---
schema_version: "secwatch.filing_event.v1"
accession: "0001610618-23-000102"
form_type: "8-K"
ticker: null
cik: "0001610618"
company_name: "Cidara Therapeutics, Inc."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T01:12:03.582393+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cidara receives Nasdaq delisting notice for bid price below $1.00; requests hearing

## Summary
- Nasdaq notified Cidara on Nov 9, 2023 that bid price closed below $1.00 for 30 consecutive trading days.
- Company is not eligible for compliance period due to prior Panel Monitor imposed by Nasdaq.
- Cidara requested a hearing on Nov 16, 2023 to present a compliance plan and seek additional time.
- Hearing request stays delisting action until Panel renders a decision.
- No assurance that Panel will grant the requested 180-day extension or the hearing.

## SEC filing metadata
- accession: 0001610618-23-000102
- form_type: 8-K
- cik: 0001610618
- company_name: Cidara Therapeutics, Inc.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610618/000161061823000102/0001610618-23-000102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610618/000161061823000102/cdtx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001610618-23-000102
- JSON: https://secwatch.observer/filing/0001610618-23-000102.json
- Plain text: https://secwatch.observer/filing/0001610618-23-000102.txt

## Key facts
- Listing & Compliance Notices
  Cidara Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: November 9, 2023, Cidara Therapeutics, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualification Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding November 6, 2023, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). As a result of the Nasdaq Hearings Panel (the “Panel”) imposing the previously discl
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061823000102/0001610618-23-000102-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.